Browsing NTNU Open by Author "Selnes, Per"

Now showing items 1-9 of 9

    • The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial 

      Chwiszczuk, Luiza; Breitve, Monica Haraldseid; Kirsebom, Bjørn-Eivind; Selnes, Per; Fløvig, John Christian Jøraholmen; Knapskog, Anne Brita; Skogseth, Ragnhild Eide; Hubbers, Jessica; Holst-Larsen, Elin; Rongve, Arvid (Peer reviewed; Journal article, 2023)
      Background: Currently, there are no disease-modifying pharmacological treatment options for dementia with Lewy bodies (DLB). The hallmark of DLB is pathological alpha-synuclein (aS) deposition. There are growing amounts ...

    • Cerebrospinal fluid levels of amyloid beta 1-43 mirror 1-42 in relation to imaging biomarkers of Alzheimer's disease 

      Almdahl, Ina; Lauridsen, Camilla; Selnes, Per; Kalheim, Lisa Flem; Coello, Christopher; Gajdzik, Beata; Møller, Ina; Wettergreen, Marianne; Grambaite, Ramune; Bjørnerud, Atle; Bråthen, Geir; Sando, Sigrid Botne; White, Linda; Fladby, Tormod (Journal article; Peer reviewed, 2017)

    • Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease 

      Kirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Torsetnes, Silje Bøen; Gisladottir, Berglind; Brix, Britta; Eugeen, Vanmechelen; Bråthen, Geir; Hessen, Erik; Aarsland, Dag; Fladby, Tormod (Journal article; Peer reviewed, 2018)
      Introduction The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that ...

    • A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease 

      Wightman, Douglas P.; Jansen, Iris E.; Savage, Jeanne E.; Shadrin, Alexey; Bahrami, Shahram; Holland, Dominic; Rongve, Arvid; Børte, Sigrid; Winsvold, Bendik K S; Drange, Ole Kristian; Martinsen, Amy E.; Skogholt, Anne Heidi; Willer, Cristen; Bråthen, Geir; Bosnes, Ingunn; Nielsen, Jonas Bille; Fritsche, Lars; Thomas, Laurent; Pedersen, Linda Margareth; Gabrielsen, Maiken Elvestad; Johnsen, Marianne Bakke; Meisingset, Tore Wergeland; Zhou, Wei; Proitsi, Petroula; Hodges, Angela; Dobson, Richard; Velayudhan, Latha; Sealock, Julia; Davis, Lea K.; Pedersen, Nancy L.; Reynolds, Chandra A.; Karlsson, Ida K.; Magnusson, Sigurdur; Stefansson, Hreinn; Thordardottir, Steinunn; Jónsson, Pálmi V.; Snædal, Jon; Zettergren, Anna; Skoog, Ingmar; Kern, Silke; Waern, Margda; Zetterberg, Henrik; Blennow, Kaj; Stordal, Eystein; Hveem, Kristian; Zwart, John Anker Henrik; Athanasiu, Lavinia; Selnes, Per; Saltvedt, Ingvild; Sando, Sigrid Botne; Ulstein, Ingun; Djurovic, Srdjan; Fladby, Tormod; Aarsland, Dag; Selbæk, Geir; Ripke, Stephan; Stefánsson, Kári; Andreassen, Ole; Posthuma, Danielle (Journal article; Peer reviewed, 2021)
      Late-onset Alzheimer’s disease is a prevalent age-related polygenic disease that accounts for 50–70% of dementia cases. Currently, only a fraction of the genetic variants underlying Alzheimer’s disease have been identified. ...

    • Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers 

      Jansen, Iris E.; van der Lee, Sven J.; Gomez-Fonseca, Duber; de Rojas, Itziar; Dalmasso, Maria Carolina; Grenier-Boley, Benjamin; Athanasiu, Lavinia; Bahrami, Shahram; Bergh, Sverre; Djurovic, Srdjan; Fladby, Tormod; Jarholm, Jonas Alexander; Knapskog, Anne Brita; Pålhaugen, Lene; Saltvedt, Ingvild; Selbæk, Geir; Selnes, Per; Andreassen, Ole; Shadrin, Alexey; Skoog, Ingmar; Soininen, Hilkka; Tsolaki, Magda; Van Broeckhoven, Christine; Van Dongen, Jasper; van Swieten, John C.; Vandenberghe, Rik; Vidal, Jean-Sébastien; Visser, Pieter J.; Vogelgsang, Jonathan; Waern, Margda; Wagner, Michael; Wiltfang, Jens; Wittens, Mandy M.J.; Zetterberg, Henrik; Zulaica, Miren; van Duijn, Cornelia M.; Bjerke, Maria; Engelborghs, Sebastiaan; Jessen, Frank; Teunissen, Charlotte E.; Pastor, Pau; Hiltunen, Mikko; Ingelsson, Martin; Clarimón, Jordi; Sleegers, Kristel; Ruiz, Agustín; Ramirez, Alfredo; Cruchaga, Carlos; Lambert, Jean-Charles; van der Flier, Wiesje M. (Peer reviewed; Journal article, 2022)
      Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European ...

    • Glial activation and inflammation along the Alzheimer's disease continuum 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind; Henjum, Kristi; Selnes, Per; Gisladottir, Berglind; Wettergreen, Marianne; Torsetnes, Silje Bøen; Grøntvedt, Gøril Rolfseng; Waterloo, Knut; Aarsland, Dag; Nilsson, Lars; Fladby, Tormod (Journal article; Peer reviewed, 2019)
      Background Neuronal and glial cell interaction is essential for synaptic homeostasis and may be affected in Alzheimer’s disease (AD). We measured cerebrospinal fluid (CSF) neuronal and glia markers along the AD continuum, ...

    • Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind Seljelid; Richter, Grit; Pålhaugen, Lene; Gisladottir, Berglind; Siafarikas, Nikias Ioannis; Nakling, Arne Exner; Rongve, Arvid; Bråthen, Geir; Grøntvedt, Gøril Rolfseng; Gonzalez, Fernando; Waterloo, Knut; Sharma, Kulbhushan; Karikari, Thomas; Vromen, Eleonora M.; Tijms, Betty M.; Visser, Pieter J.; Selnes, Per; Kramberger, Milicia G.; Winblad, Bengt; Blennow, Kaj; Fladby, Tormod (Peer reviewed; Journal article, 2023)
      Background Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal ...

    • Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort 

      Jarholm, Jonas Alexander; Bjørnerud, Atle; Dalaker, Turi Olene; Akhavi, Mehdi Sadat; Kirsebom, Bjørn-Eivind; Pålhaugen, Lene; Nordengen, Kaja; Grøntvedt, Gøril Rolfseng; Nakling, Arne Exner; Kalheim, Lisa Flem; Almdahl, Ina Selseth; Teceläo, Sandra Raquel Ramos; Fladby, Tormod; Selnes, Per (Peer reviewed; Journal article, 2023)
      Background: Atrophy of the medial temporal lobe (MTL) is a biological characteristic of Alzheimer’s disease (AD) and can be measured by segmentation of magnetic resonance images (MRI). Objective: To assess the clinical ...

    • Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients 

      Kirsebom, Bjørn-Eivind; Richter, Grit; Nordengen, Kaja; Aarsland, Dag; Bråthen, Geir; Tijms, Betty M; Visser, Pieter Jelle; Nilsson, Johanna; Selnes, Per; Kramberger, Milica G.; Winblad, Bengt; Waterloo, Knut; Gísladóttir, Berglind; Blennow, Kaj; Fladby, Tormod (Peer reviewed; Journal article, 2022)
      Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF ...